Effects of an Inhibitor of Sodium-glucose Cotransporter 2 for Type 2 Diabetes Mellitus with Nonalcoholic Fatty Liver Disease (NAFLD).
Phase of Trial: Phase II
Latest Information Update: 24 Jul 2017
At a glance
- Drugs Canagliflozin (Primary)
- Indications Non-alcoholic fatty liver disease; Type 2 diabetes mellitus
- Focus Therapeutic Use
- 21 Jul 2017 Status changed from not yet recruiting to recruiting.
- 24 May 2016 New trial record